STOCK TITAN
  1. Home
  2. Sec-filings
  3. RIGL
  4. [Form 4] RIGEL PHARMACEUTICALS INC Insider Trading Activity

RIGEL (RIGL) director Kamil Ali-Jackson receives 5,750-share RSU board grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Ali-Jackson Kamil reported acquisition or exercise transactions in this Form 4 filing.

RIGEL PHARMACEUTICALS INC director Kamil Ali-Jackson received a stock grant tied to board service. The Form 4 shows an award of 5,750 shares of Common Stock at no cash cost, delivered as Restricted Stock Units. These units will fully vest on the date prior to the company’s next Annual Meeting, as long as the director continues serving on the Board. After this grant, the director holds 15,125 shares of Common Stock directly.

Positive

  • None.

Negative

  • None.
Insider Ali-Jackson Kamil
Role null
Type Security Shares Price Value
Grant/Award Common Stock 5,750 $0.00 --
Holdings After Transaction: Common Stock — 15,125 shares (Direct, null)
Footnotes (1)
  1. [object Object]
RSU grant size 5,750 shares Restricted Stock Unit award to director on 2026-05-15
Grant price $0.00 per share Equity compensation, not an open-market purchase
Post-transaction holdings 15,125 shares Common Stock directly owned after the RSU grant
Vesting condition Fully vests before next Annual Meeting Subject to continuous Board service by the director
Restricted Stock Unit financial
"The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person."
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Annual Meeting financial
"The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service"
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.
Common Stock financial
"The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person."
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ali-Jackson Kamil
(Last)(First)(Middle)
RIGEL PHARMACEUTICALS, INC.
611 GATEWAY BLVD, SUITE 900
(Street)
SOUTH SAN FRANCISCO CALIFORNIA 94080
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
RIGEL PHARMACEUTICALS INC [ RIGL ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/15/2026A5,750(1)A$015,125D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors.
/s/ Raymond Furey (Attorney-in-Fact)05/19/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did RIGL director Kamil Ali-Jackson report on this Form 4?

Kamil Ali-Jackson reported receiving 5,750 shares of RIGEL PHARMACEUTICALS Common Stock as a Restricted Stock Unit award. The grant is compensation for service on the Board and involves no cash purchase by the director.

How many RIGL shares did Kamil Ali-Jackson receive and at what price?

The director received 5,750 shares of RIGEL PHARMACEUTICALS Common Stock at a price of $0.00 per share. This indicates a compensation-related equity award rather than an open-market stock purchase transaction.

When do Kamil Ali-Jackson’s RIGL Restricted Stock Units vest?

The Restricted Stock Units fully vest on the date prior to RIGEL PHARMACEUTICALS’ next Annual Meeting. Vesting is conditioned on the director’s continuous service on the company’s Board of Directors through that vesting date.

How many RIGL shares does Kamil Ali-Jackson hold after this transaction?

Following the grant, Kamil Ali-Jackson holds 15,125 shares of RIGEL PHARMACEUTICALS Common Stock directly. This figure reflects the updated ownership position reported in the Form 4 after including the new Restricted Stock Unit award.

Was this RIGL Form 4 transaction an open-market buy or a compensation grant?

The filing shows a compensation grant, not an open-market purchase. Code “A” identifies a grant or award, and the 5,750 shares were issued at $0.00 per share as Restricted Stock Units for Board service.

Does the RIGL Form 4 mention any conditions on the stock award vesting?

Yes. The Form 4 footnote states the Restricted Stock Units will vest only if Kamil Ali-Jackson continues to serve on RIGEL PHARMACEUTICALS’ Board of Directors through the date prior to the next Annual Meeting.